0000000000925621

AUTHOR

H.‐p. Lipp

showing 1 related works from this author

Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer

2007

Angiogenesis is the process by which new blood vessels are created from pre-existing vessels. It is essential for the growth and development of normal cells and tissues during embryonic and neonatal development and of tumour cells. Solid tumours rely on having an extensive network of blood vessels for growth and survival. The key mediator of angiogenesis, vascular endothelial growth factor-A (VEGF-A), is critical for the growth of tumours and their subsequent metastasis and is known to initiate angiogenesis. Bevacizumab is a humanized immunoglobulin G monoclonal antibody that binds to VEGF with high specificity, thereby blocking VEGF-mediated signalling pathways and thus angiogenesis. Clini…

Antimetabolites AntineoplasticBevacizumabColorectal cancerAngiogenesisNeovascularization PhysiologicAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMetastasisNeovascularizationchemistry.chemical_compoundHumansMedicineDrug InteractionsPharmacology (medical)Neoplasm MetastasisSurvival ratePharmacologybusiness.industryAntibodies Monoclonalmedicine.diseaseBevacizumabSurvival RateVascular endothelial growth factorchemistryImmunologyMonoclonalCancer researchDrug Therapy CombinationFluorouracilmedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct